Translating genomics: are we connecting the dots?
Translation of pharmacogenomics to public health action has been at the epicenter of the life sciences research and development (R&D) agenda since the completion of the Human Genome Project (HGP) a decade ago. In the current postHGP ('postgenomics') era, the inter con nect ed ness of biotechnology designers, innovators and consumers of scientifi c knowledge might appear too obvious a need to mention. After all, why design and inno vate a product (for example, a pharmacogenomics test) if it were not to meet the needs of the attendant users? Th e southern African concept of ubuntu epito mizes the mutual interdependency of human beings, be they scientists or citizens, and the message that 'no person is an island' [2] . One would think the spirit of ubuntu is already wellestablished among the expert communities that comprise the postgenomics inno va tion ecosystem.
But experts, by virtue of disciplinary hyper specialization that is endemic in the postgenomics era, suff er from professional blind spots [1, 3, 4] . Such siloed knowledge is a barrier to putting genomics to action. Nearly a century ago, Th orstein Veblen noted 'trained incapacity' , referring to acquired blind spots in profes sions or 'learned inability' to maintain a collateral vision due to extensive specialist training [4] . Recent studies support Veblen's theory. For example, a scoping analysis of 344 studies in health and allied sciences addressing patients' , clinicians' and researchers' priorities for research found that only nine considered the extent to which questions posed by researchers match questions of relevance to patients and clinicians [5, 6] .
Contributions by Veblen and other scholars [4, 714] have collectively underscored the risks associated with claiming a 'cardcarrying' member status within one's own fi eld or profession, be it public health, pharmacology, genetics, industry, government, social science, bioethics or moral philosophy. The risks include an 'echo chamber effect' , where one communicates primarily with those who are members of the same disciplinary culture, or think through the same disciplinary lens. This interferes with transdisciplinary synthesis of scientific evidence and can perpetuate or augment the existing knowledge silos in genome medicine [13, 15] .
Innovation actors operating with vastly different moti va tions and aspirations, when left unchecked, cannot produce knowledge synchronously at a scale that meets the demands of largescale postgenomics applications. While one may reasonably argue that synchronous knowledge production in science is not always important (in undirected 'blue sky research' , for instance), applied research such as public health pharmacogenomics requires complex collaboration and coordination to generate innovative health products that can be used for population health. One witnesses this in the current global pharmacogenomics research that is materializing in diverse 'scientific cultures' [3, 13, 16, 17] . Consistent with this, a scoping study associated with the UK James Lind Alliance report (Tackling Treatment Uncertainties Together) on the broader importance of coordinated R&D in health sciences has underscored the need for co ordination between upstream (research agenda setting) and downstream (implementation and uptake) research: The evidence for informing decisions about health treatments is based largely on research agendas set in an uncoordinated fashion by academics and industry. The launch of the National Health Services (NHS) Research and Development pro gramme, in 1991, instigated a needsled pro gramme of commissioned research to counter balance the responsive programmes which rely primarily on researchers suggesting potential research projects to funders. [5] In addition to professional blind spots in science, previous discussions of genomics have exposed otherwise unchecked and embedded selfinterests, whether from academia, government, industry, media or patient advo cacy groups, not to mention bioethicists, social scientists and philosophers reflecting on genomics, innovation and society. Scientists and technologydriven expert commu nities tend to advocate, for example, that 'more research is needed' , but policymakers and patient advocacy groups need to act when 'facts are uncertain and stakes are high' (for an excellent overview of the tensions between and opportunities for better cooperation between scientists and policymakers in the face of scientific uncertainties, see the discussion by Bernard Choi et al. [1] and Jerome Ravetz [18] ).
Our working premise is that to truly enable a robust public health pharmacogenomics R&D landscape, post genomics science warrants a 'third pillar' whereby the political determinants of health are recognized and taken seriously, as much as the social and biological deter minants of health [1923] . This paper introduces, first, the concept and project of 'Mode 2' knowledge production that typifies post genomics R&D to a large extent [22, 2427] . It is applied and collective innovationoriented, and coproduced in multiple scales and at multiple locales, both inside and outside academia. This is contrasted with 'Mode 1' knowledge production, which is narrowly framed, often confined to academia, and has the ethos of 'knowledge for its own sake' . We provide examples of Mode 2 know ledge in pharmacogenomics, such as citizen science, and discuss the implications for postgenomics science. By studying different modes of knowledge production in the postgenomics innovation ecosystem, innovative para meters of collective action can be defined so as to move largescale dataintensive science such as pharmaco genomics into public health practice.
Second, we discuss knowledgebased innovation as a com plex ecosystem composed of innovators ('actors') and regulators ('narrators'). This idea is based on the tenet that one cannot critically examine, in a singularly disinterested manner, the very innovation system in which one is embedded as an innovation actor (for example, a principal investigator conducting a pharmaco genomics project) [2123] . To achieve robust translation of pharmacogenomics to public health action, we propose a nested postgenomics knowledge governance system composed of firstorder narrators (for example, social scientists, philosophers and bioethicists cognizant of technology nuances) situated at arm's length from innovation actors. Yet, secondorder narrators (for example, an independent, possibly crowdfunded think tank alliance of citizen scholars) are also crucial to improve selfcalibration and accountability in a post genomics knowledge ecosystem.
Third, to illustrate knowledgebased innovation as a complex ecosystem, we propose a Web 2.0driven 'wiki governance' approach that goes beyond traditional public engagement or citizen participation models to close the gap between research participants and researchers by giving participants and publics the ability to collaborate in pharmacogenomics governance.
'Mode 2' knowledge production and massively collaborative distributed science: letting the 'academic genie' out of the ivory tower?
Pharmacogenomics is now an old science. With the introduction of genomics science and technology over the past two decades, it has evolved from the predecessor field of pharmacogenetics that has mid20th century origins in early studies of monogenic variations in drug metabolism. Yet progress in pharmacogenomics science is neither driven nor influenced by technology alone. In the current postgenomics era, there have been seismic shifts in the way scientific knowledge is produced.
Evidenced by various open science initiatives connected by digital media and Web 2.0, postgenomics knowledge is coproduced in a highly distributed manner. It is extending well beyond the cloistered halls of academia and the laboratory bench space to hitherto unprece dented locales. It impacts, and is being impacted by, new stakeholders such as citizen scientists, developing countries and patient advocacy groups [3, 16, 17] . These stakeholders are contributing, in some cases, to complex scientific tasks [27] .
We offer a new perspective that focuses on how scien tific knowledge is coproduced in order to under stand the emergent forms of collaboration in 'postgenomics pharmacogenomics' . Such a perspective moves us away from codified static knowledge where making informa tion available, transmissible and reproducible across scientific sites was traditionally at the core of the science enterprise. Here, we emphasize the 'knowing' aspect of knowledge production: how is knowledge produced, forum for contributors to work on a complex unsolved mathematical problem. He posed the question: "Is massively collaborative mathematics possible?" He then set out the problem, his ideas about it and an invitation for others to contribute to its solution. 27 people made more than 800 comments, rapidly developing or discarding emerging ideas. In just over a month, the problem was solved. Together they not only solved the core problem, but a harder generalisation of it. In describing this, Gowers said, "It felt like the difference between driving a car and pushing it. " [29] This resonates well with Michael Gibbons and colleagues' concept and project of 'Mode 2' knowledge production [2427] . Mode 2 knowledge is a simultaneous 'coproduction' by a multitude of heterogeneous actors, both experts and nonexperts/nonprofessionals, dis persed in diverse geographical and disciplinary locales and scales. Mode 2, as explained by Barbara Prainsack, is 'where knowledge production takes place inside and outside of organisations and institutions that have ceased to fit within any clear categories' [30] .
The concept firmly recognizes the 'social construction' of scientific knowledge and that the boundaries between science, technology and society are highly porous. That is, scientific knowledge is a coproduct of technology and natural laws, as well as human values and epistemologies embedded in scientific inquiry. This contrasts sharply with the scientific practices of the original founders of pharmacogenetics in the 1950s, where knowledge was produced within the secluded territory of academia using a 'singlescientist, singleproject' model rather than collective innovation and massively collaborative distributed science (Table 1) .
Mode 2 knowledge production is not without its critics, particularly traditional experts, academics and technology centered communities who are not necessarily ready to let the 'knowledge production genie' out of the academic ivory tower, that is, from their power domains and controlled territories (for a detailed discussion of this tension in Mode 2 knowledge between scientists and nonexpert communities, see the excellent overview by Gibbons et al. [24] ). Yet, while there are limits to the extent to which nonexperts and nonprofessionals may contribute to scientific inquiry, it is clear that their role is not relegated to the traditional passive one where they are simply asked to adopt and accept the innovations produced singlehandedly by experts [31] .
For pharmacogenomics R&D to be robustly linked to public health action on the ground, we need to recognize that the entire scientific trajectory is open to influences by social systems and human values that remain unchecked in discourses around knowledgebased inno vation. The choice and framing of scientific hypotheses, experimental methodology and interpretation of data can all be influenced by experts' and their institutions' embedded value systems that are not always made explicit [3033] . Hence, Mode 2 is not a departure from pure knowledge production as such, but an attempt to make the politics of knowledge and the embedded human values and motives transparent and, thus, render knowledge production more robust, actionable and stand the test of extended peerreview by a broader diversity of stakeholders. In a sense, Mode 2 is not new because the boundaries between natural/technical and social systems are highly porous, and have always been (see the excellent autobiographical account on this subject by Brian Wynne [32] ). Yet, Mode 2 is novel for offering a coherent explanation for how human values and ways of knowing expressly impact what gets to be produced as scientific knowledge [23] .
In opening up the hitherto cloistered halls of academia to a broader range of innovation actors, Mode 2 redistributes power and thus facilitates a more open and collective participation in science. This does not mean that Mode 2 is code for publicprivate partnerships or 'selling out' science to free markets. It fundamentally moves beyond these artificial binaries and false demarca tions between science and society. It highlights the creative potential of intersections and interactions (for example, cooperation, competition, conflict or post competitive collaboration) among the innovation actors for a more deliberated, open and robust knowledge pro duc tion. Helga Nowotny and colleagues observe that: 'Mode 2' is not only a concept, inherently open to manipulation or exploitation by others (even in ways of which we may disapprove); it is also a project, an example of the social distribution of knowledge, which it seeks to describe. … Closure of the 'Mode 2' debate is neither possible nor desirable. The project has many of the characteristics of the much more open knowledge Table 1 . Modes of knowledge production in the post-genomics era
Mode 1 knowledge Mode 2 knowledge
Historically prevailed since the origin of modern thought associated with the Enlightenment and the rise of positivism more than four centuries ago -accompanied by a firm belief in science as 'special' , 'a thing apart' , 'value-neutral' and invariably an objective human activity seeking a 'singular truth'
A recent challenge to knowledge in 'mode 1' -in recognition that uncertainty and 'unknown unknowns' are ever present in science:
Even the research questions and study designs posed by scientists (not only the outcome and output of science) have unchecked assumptions and embedded value systems at play, that is, science is not a value-neutral or special activity to be placed on an 'untouchable pedestal'
Recognized particularly in scientific fields with vast uncertainties such as global warming, climate change and nanotechnology
Produced by experts based on a linear and positivist 'science push' model of innovation 'Co-produced' by both experts and non-experts/non-professionals such as citizen scientists, various publics and end-users of scientific innovation; 'push-and-pull' model of innovation production systems that it is attempting to analyse wide social distribution, transdisciplinarity, the need for social robustness, and the creative potential of controversies. [26] Mode 2 knowledge and the biological citizen
As science and knowledge production have become more dispersed with new actors such as citizen scientists or practices such as crowdsourcing and directtoconsumer genetic testing, Mode 2 has merged with another emerging postgenomics characteristic: biological citizens. These are entrepreneurial citizens who are autonomous, selfgoverning and increasingly conceptualizing them selves in biological terms and ostensibly taking responsibility for their own health. Biological citizenship is also accompanied with the rise of patient advocacy and health activism [34, 35] . Together with opening up previously untouchable domains of scientific enterprise, Mode 2 knowledge symbolizes an ongoing experiment that will be further shaped in ways that are currently unpredictable by the intersections and divergences of technical, social and economic vectors and biological citizenship. Still, one thing is certain: there is much to be gained in reducing research waste [6] by more closely engaging expert communities, nonprofessionals and endusers through recognition of Mode 2 knowledge production processes and concepts.
Beyond Mode 2: complex collaboration and collective action in the post-genomics innovation ecosystem
There is a large translation gap in moving genomics technology and basic science discoveries to successful innovation. Muin J Khoury and colleagues [36] found that only 3% of the US National Institutes of Health (NIH) funding was targeted for downstream translational research. The study did not examine other funding sources or clinical implementation taking place under a variety of mechanisms, including traditional clinical practice, quality and safety initiatives or research. Nonetheless, this finding is important as it points to the small fraction of resources dedicated to translational research compared with basic science [36] . Further investments in translational research and recognition of the role to be played by Mode 2 knowledge in linking basic research to public health practice may remedy this translation gap in genome medicine. The recent NIH initiative to establish the National Center for Advancing Translational Sciences (NCATS) to pursue opportunities for disruptive translational innovation is consistent with Mode 2 genomic knowledge production [37] . While Mode 2 knowledge articulates a new lens to examine and understand postgenomics knowledge production, it does not necessarily embody a 'systems orientation' to innovation. We claim that there is a need to complement and further advance the Mode 2 concept by rethinking postgenomics public health as 'knowledge ecologies' that collectively form an innovation ecosystem. There are compelling reasons why such an ecosystem approach is important for public health pharmaco genomics action on the ground.
First, the multiplicity of actors that enables innovations in the emerging field of public health pharmacogenomics demands coordination and steering capabilities for the entire knowledge ecosystem that underpin and sustain such innovation. Second, it would be naive to assume that innovation actors invariably share complementary or mutually compatible aspirations and aims. Nor can one assume that these motives are immediately made trans parent to others. The ethos of advocacy ('change manage ment' , or bringing about a change for public health action) is not often cultivated within traditional academic or scientific expert communities, let alone in the course of training as a graduate student in pharmacogenomics. Third, complex collaboration is needed when knowledge crosses organizational, disciplinary or national boun daries, and when actors have differences in research practices and methods, ontologies, human values and epistemologies [10, 11, 13] . Fourth, there is an increasing recognition that knowledgebased postgenomics inno va tions demand cultivation of ongoing, iterative and mutual learning among the innovation actors so as to enable dynamic and sustainable collective innovation [31] .
These considerations together raise collective action problems as well as opportunities to scale up genomics for applications in public health [38] . Traditional modes of knowledge sharing and learning practices among experts, such as annual international meetings and traditional expertsdriven peerreview processes, are not always well equipped to translate pharmacogenomics to public action on the ground. Without a steering function, innovations can be stifled or result in redundant research and duplication or waste.
A new theoretical lens is required to conceptualize knowledgebased innovation as a complex ecosystem of 'innovation actors' and 'innovation narrators' . Actors often (and ought to) have selfinterests that limit their ability to evaluate the very innovation ecosystem in which they are embedded. On the other hand, it would be naive to place narrators automatically 'above the fray' and think that they will have no selfinterests. As with philanthropists, government research funders, academics, industry or the media, firstorder narrators also may have selfinterests that need to be made explicit. For example, while moral philosophers, bioethicists and social scien tists have taken up the task of social critique and study of the social construction of science and technology, their normative conclusions (for example, an ethical/unethical technology, person, industry), as with natural scientists, can also be subject to infl uences by their own value systems and personal career agendas [19, 2123] .
One of the unique aspects of the Human Genome Project, in contrast to traditional disciplinebound sciences such as pharmacology, was the intentional funding of research into the attendant ethical, legal and social issues (ELSIs) a research mandate that continues to the present day in that all research proposals submitted to the US National Human Genome Research Institute must include activities in the ELSI space.
While there is no doubt that these eff orts remain crucial, and have moved genomics R&D increasingly to the Mode 2 knowledge space (relative to pharmacology, for example), there is growing debate within the ELSI community where the next direction(s) should be [12, 3942] . It is noteworthy that pharmacogenomics is a 'hybrid' fi eld that draws from both genomics and pharmacology. While genomics now resides within the Mode 2 space, pharmacology as a discipline has lagged behind. For example, pharmacology research does not routinely carry out ELSI research as a contrast to genomics R&D. Indeed, if we refl ect on the panoply of contemporary biomedical disciplines in existence, social pharmacology is 'missing' or kept silent, and sadly does not exist as a formal university department, despite the legitimate recognition of social medicine or social psychiatry in 21st century universities. Th is is an important gap that is impacting pharmacogenomics as a hybrid science that rests in part on pharmacology scholarship.
As a way forward, a critical examination of how bio ethics questions are framed, and the previously un challenged role of bioethics as an innovation regulator, will be important considerations in planning for trans lation of pharmacogenomics innovations to public health practice. To this end, it is interesting to note that the myth of bioethics and social science as being inclusive and primarily intended to serve the best interests of publics and marginalized populations, or capturing the broad and reallife issues attendant to pharmaco genomics, quickly dissolves once one steps into a moral philosophy offi ce uninterested in contexts or technology nuances, or a careerist social science laboratory and, thus, observe the more haphazard and messy realities of how 'bioethicsasregulator' might work in practice. For example, in an analysis of the social and technical expecta tions surrounding pharmacogenetics and the attendant perceived role of bioethicists as regulators, Adam Hedgecoe has highlighted that: [A]lmost a decade after bioethical debate around pharmacogenetics started, and in contrast to the profession's selfperception as a form of regulator, bioethicists still largely restrict themselves to reviews of possible ethical issues raised by this technology, rather than critiquing others' positions and arguing for specifi c points of view. … [B]ioethicists tend to: accept unquestioningly scientists' expectations about the development and ethical issues raised by pharmacogenetics; ignore contributions from bioethicists who do question these expectations; and engage in an ethical debate, the boundaries of which have been laid down and defi ned by academic and industry scientists. [39] .
Hence, secondorder narrators (for example, an independent and possibly crowdfunded thinktank alliance of citizen scholars, representatives of hitherto marginalized groups, and knowledge endusers engaged in public scholarship) are crucial [16] to prevent fi rst order narrators from gaining undue excessive power that can be potentially abused or incorrectly targeted in the course of steering innovations. Figure 1 illustrates our proposed conceptual model of a postgenomics inno vation ecosystem and its elements.
Undoubtedly, the type and range of actors to be included in such an ecosystem are diverse. Th e examples shown are intended to provide an initial conceptual sample of the possible constituents and their juxtaposition to the innovation narrators of the fi rst and second orders.
In the next section, we introduce a new but related concept: 'wikigovernance' . We situate it within the broader framework of citizen participation in open science so as to concretely defi ne the ways in which the innovation ecosystem constituents, as well as knowledge coproduction, can be governed in the spirit of Mode 2 distributed science.
Wiki-governance for knowledge-based innovation ecosystems
Building on developments in agricultural biotechnology and nanotechnology in the 1990s and 2000s, genomics research has made great strides in incorporating public support to close a perceived 'agency gap' between researchers and research participants and the greater citizenry. Th is evolution, witnessed in forums such as citizen juries and consensus conferences, is viewed positively in academic circles for substantive, normative and instrumental reasons alike [42, 43] . It has also been observed empirically that a diversity of publics desires a role in developing science and technology policy, if not merely an off ering of general acceptance of a research project or domain [44, 45] . Models of science and tech nology public engagement have burgeoned in the past two decades, though to fully understand their under pinnings one must situate them in the larger historical context of social and democratic theory, political science and governance studies. At the same time, a word of caution is necessary: applying 'democracy' to post genomics R&D may raise false expectations about bind ing political norms. Th e concept of public or citizen 'participation' (or better, 'collaboration'), on the other hand, achieves a more suitable framework for positioning public engagement in postgenomics governance and innovations.
Th e idea of multiple levels of citizen participation in decisionmaking can be traced back, at least in modern (and Western) times, to Sherry Arnstein's infl uential 1969 article on the eight levels of citizen participation, ranging categorically from 'nonparticipation' to 'tokenism' to 'citizen power' [46] . More recently, publicly funded research agencies are engaging in open science as noted above [28] , and in the spirit of transparency, state and municipal governments around the world are imple menting open data strategies whereby government collected data are distributed online openly so that publics can take the data to either monitor government eff ectiveness or brainstorm about creating new ways to make public services more userfriendly, more effi cient and more interactive.
Many state governments, such as New Zealand, Estonia, Russia and Brazil, are also moving past delibera tive democracy to 'participatory democracy' , creating 'e democracy' forums whereby publics can initiate legislative proposals, participate in public hearings, or draft bills as New Zealand's wikidrafted Policing Act 2008 demonstrates [47] . Another example of the larger context of public engagement is the concept of 'upstream engagement' , seen especially in science and technology fi elds such as nanotechnology, where publics are included at the embryonic agendasetting stages of policymaking so as to remedy the epistemic and communicative estrangement between putative experts and lay publics and encourage more dialogue, coproduction of know ledge and, ultimately, collaboratively crafted outputs [48] .
All of these examples work towards 'empowering' individuals to harness their various skills to achieve collective innovation. However, some models of public engagement, albeit laudable, seem to assume a passively consumptive public that can only digest information unidirectionally disseminated (for example, posting of policies on a website). Other models may involve so called public 'community members' (for example, town hallstyle panels), but in fact may be what Arnstein would label 'placation' and a symbol of tokenism [46] that is, a facade of inclusiveness that in reality merely acts to legitimate the decisions of science experts.
Indeed, some authors have found that (democratic) deliberation, as the name implies, focuses on inputs without any guarantee of collaborative outputs. Political science analyses indicate that public communication and public consultation resembles more a monologue than dialogue, and even in situations of bidirectional public participation, there is no guarantee of actionable steps beyond processes (for example, gathering diverse viewpoints), especially for the creation of innovative implementable solutions [49, 50] . Th us, there is a large potential for the greater citizenry to be lulled into a false reassurance of a remedied 'agency gap' or a responsible and representative science and science policymaking agenda. Th is potential certainly is nestled in the post genomics fi eld, where so much of the funding comes from taxpayerendowed public (state) entities, yet experience and expertise increasingly lay with decentered, nonstate actors [51] . Loss of public trust and support would be detrimental to postgenomics research in general and would also stall its translation to successful innovations [52] .
In light of our proposed innovation and knowledge ecosystem to put public health pharmacogenomics into In a knowledge ecosystem such as public health pharmacogenomics, innovation actors co-produce knowledge and calibrate their actions and trajectory through open and transparent mutual learning, enabled by recursive practices such as wiki-governance. First-order narrators, who are situated at a crucial but not imperceptible analytical distance from the innovation actors, can examine and steer the innovation ecosystem trajectory, thereby contributing to collective action in the innovation ecosystem. Second-order narrators (for example, innovation observatories represented by citizen scholars, hitherto marginalized groups, and patients) can further keep the fi rst-order narrators in check by making them more accountable, and by rendering visible their actions and situating them in a socio-technical context. Defi nitions: phase 1 translation (T1) aims to advance a basic genomebased discovery into a candidate health application (for example, a pharmacogenomics test); phase 2 translation (T2) concerns the development of evidence-based guidelines for a pharmacogenomics application; phase 3 translation (T3) aims to connect evidence-based guidelines with health practice, through delivery, dissemination and diff usion research; phase 4 translation (T4) evaluates the real world health outcomes of a pharmacogenomic application. See Khoury et al. [36] for the T1 to T4 translation research continuum and its actors. action, one model that may overcome some of these pitfalls and offer a better avenue for translating phar ma co genomics to public health action is 'wikigovernance' , which horizontalizes the traditional decisionmaking hierarchy and situates itself within a more globally networked and mutualitydriven innovation ecosystem (Table 2 ) [53, 54] . Importantly, wikigovernance grafts the social and political science fields onto the genomics infrastructure by giving publics the ability to shape the innovation trajectory directly and collaboratively. Wiki governance may be especially useful in biobanks, which are crucial for public health pharmacogenomics. While no biobanks have yet fully adopted the model, several have embraced variations of it, including the reflexive governance approach of the UK Biobank [55] and the adaptive governance approach of the (Canadian) BC Generations Project [56] . Postgenomics R&D is increasingly conducted with and initiated from biobanks, not only in basic sciences, but also in epidemiology sur veillance where largescale datasets (as in biobanks) can concretely inform R&D. In biobanks, a full embrace of the model to accelerate the nascent field of public health pharmacogenomics would entail managers and adminis tra tors ('biobank builders') developing a secure online forum where publics could register and collaborate in pro posing, drafting, commenting on, and amending bio bank governance structures, protocols, strategies and policies. One of the main distinguishing features of wiki governance is not only its embrace of social mediadriven technology, but also the use of structured coordination via issue framing and role differentiation so that individuals can choose the opportunities that best exploit their skills and represent their interests. For example, some individuals may have niche expertise in legal areas such as intellectual property, and thus may want to comment on or draft a biobank policy on commerciali zation or benefit sharing, whereas other individuals may have a background or interest in genetics or bioethics and decide to focus only on those particular areas. Wiki governance applications generally do not adhere to a completely libertarian approach. In the example of biobanks, the biobank's management (or similar) com mit tee would act as final arbiters in determining if and when a structure, policy or protocol should be adopted as final, and whether its contents are scientifically, ethically and legally valid. Moreover, the model is flexible in that a continuous feedback loop is employed so that as signi ficant science, technology and sociolegal developments arise, publics can challenge the existing policies and procedures and help anticipate and shape future ones. In sum, wikigovernance expands the innovation actors' collective capacity to imagine and respond to multiple possible (multiplex) future(s) of a given novel innovation trajectory such as public health pharmacogenomics.
Some potential but not insurmountable drawbacks of wikigovernance have been noted elsewhere (for example, scaling and capital investment difficulties, the socalled digital divide, difficulties associated with draft ing normative rather than factual policies) [53] . Some have suggested that collaboration with publics will retard rather than accelerate innovations and that lack of putative expertise, consensus on certain values and interests, as well as potential marginalization of certain groups of citizens, could limit the practicality of true public engagement [57] . Yet, a compelling case can be made for the need for pooling diverse knowledge and skills in the backdrop of Web 2.0 and social media tech nology. As Andy Stirling notes, traditional linear notions of technological progress hide 'the ways important political choices over alternative directions for innovation are made at every juncture and should be as subject as other areas of policy, to democratic participation and accountability' [43] . Stirling argues that publics 'can be seen to offer means to reconcile tensions between the otherwiseestranged Enlightenment values of science and democracy' and offer 'an opportunity to be more rigorous about the uncertainties in bioscience innovation and more accountable about the exercise of power' [43] .
In postgenomics and related new specialties such as public health pharmacogenomics, where uncertainty is paramount and much knowledge remains unknown or indeterminate, models such as wikigovernance can effectively bridge science and democracy to achieve multiple pathways for citizens to rightfully envision themselves as cocreators of genomic science, policy, and successful and sustainable innovation.
Concluding remarks
Every first order action has second order consequences. With the rise of Mode 2, longheld assumptions of scientists and science are being challenged in the post genomics era what it means to be a pharmacogenomics expert or a university professor, whether science and innovation can be singularly entrusted or simply dele gated to firstorder traditional innovation narrators such as social scientists, philosophers or bioethicists, and whether academia, industry or governments can con tinue to exclude nonprofessionals [42] . Indeed, the idea of improving genomics translation for public health action, while important and essential, has hitherto bracketed out the emerging ways in which post genomics knowledge is coproduced by a multitude of stakeholders. Increasingly, genomics translation is multinodal (multiple stakeholders beyond industry and academia) and multimodal (multiple ways of knowledge produc tion). Execution of science in the postgenomics era is highly dynamic and extensively distributed, both in terms of geography or 'locales' of knowledge production [5860] and also in the range of disciplines involved in genomics evidence synthesis [61] . Michael Gibbons notes that there are important choices to be made in uni ver sities for the 21st century in reference to knowledge production in Mode 1 and Mode 2: The key questions have less to do with deciding whether a university is to be a research or a teaching institution than deciding between which modes of research and teaching to invest scarce resources. ...
[T]hese are major questions for any university and their resolution implies even more diversity of institutions than is currently available. [27] We suggest that these choices are pressuring public health and pharmacogenomics practices outside univer sities as well, for example, in regulatory agencies, govern ments, transnational organizations, thinktanks and non governmental organizations, and the life sciences, bio technology and insurance industries. The present analysis of the emerging field of public health pharmacogenomics is an invitation to think outside our own professional habitus and hold judgment upon encounters with new ways of knowledge production. Ultimately, Mode 2 moves us to build the missing third pillar in positivist postRenaissance science by bringing to the fore the political determinants of health, together with the attendant social and biological determinants.
As we move from a Mode 1 Edisonian science, where data collection and experimental design by a single principal investigator were essential loci of the scientific endeavor, to Mode 2 distributed science, where data collection is automated by nextgeneration sequencing technologies and increased connectivity among innovation actors, there is an essential need to understand the new ways of doing pharmacogenomics science that enable collective innovation for public health action [13] .
